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Rationale: Prolonged exposure to 100% O2 causes hyperoxic acute
lung injury (HALI), characterized by alveolar epithelial cell injury and
death. We previously demonstrated that the murine chitinase-like
protein, breast regression protein (BRP)–39 and its human homolog,
YKL-40, inhibit cellular apoptosis. However, the regulation and roles
of these molecules in hyperoxia have not been addressed.
Objectives: We hypothesized that BRP-39 and YKL-40 (also called
chitinase-3–like 1) play important roles in the pathogenesis of HALI.
Methods: We characterized the regulation of BRP-39 during HALI and
the responses induced by hyperoxia in wild-type mice, BRP-39–null
(2/2) mice, and BRP-392/2mice in which YKL-40 was overexpressed
in respiratory epithelium. We also compared the levels of tracheal
aspirate YKL-40 in premature newborns with respiratory failure.
Measurements and Main Results: These studies demonstrate that
hyperoxia inhibits BRP-39 in vivo in the murine lung and in vitro in
epithelial cells. They also demonstrate that BRP-392/2 mice have
exaggerated permeability, protein leak, oxidation, inflammatory,
chemokine, and epithelial apoptosis responses, and experience
premature death in 100% O2. Lastly, they demonstrate that YKL-40
ameliorates HALI, prolongs survival in 100% O2, and rescues the
exaggerated injury response in BRP-392/2 animals. In accord with
these findings, the levels of tracheal aspirate YKL-40 were lower in
premature infants treated with hyperoxia for respiratory failure who
subsequently experienced bronchopulmonary dysplasia or death
compared with those that did not experience these complications.
Conclusions: These studies demonstrate that hyperoxia inhibits BRP-
39/YKL-40, and that BRP-39 and YKL-40 are critical regulators of
oxidant injury, inflammation, and epithelial apoptosis in the murine
and human lung.
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Supplemental oxygen is commonly administered to patients with
significant pulmonary and cardiac disease to increase the delivery
of oxygen to peripheral tissues. However, very high concentra-
tions of oxygen (fractional inspired concentrations > 50%) for
prolonged periods cause hyperoxic acute lung injury (HALI).
This response is characterized by endothelial and epithelial injury
and enhanced alveolar capillary protein leak (1–6). Studies of this
response have led to the free radical theory that suggests that, in
100%O2, lung cells poison themselves by producing an excess of
reactive oxygen species (7–9).Recent studies fromour laboratory
and others have added to this pathogenic paradigm by demon-
strating that reactive oxygen speciesmediate their effects, in part,
by inducing an endothelial and epithelial cell death response with
features of apoptosis and necrosis (6, 7, 10–14). In spite of the
obvious importance of pathways that regulate these toxic re-
sponses, and the well documented variations in the ability of
inbred mice to withstand exposure to 100% O2 (6, 7, 10, 15), the
endogenous mechanisms that contribute to the control of these
responses have not been adequately defined.
The evolutionarily conserved 18-glycosyl-hydrolase family
contains true chitinases andmolecules that lack chitinase activity
(16–19). Much of the research in this area has focused on
chitinases such as acidic mammalian chitinase, which plays
a critical role in the life cycle of parasites and the pathogenesis
of T helper cell (Th) 2 and antiparasite responses (18–20).
However, the majority of the 18-glycosyl-hydrolase family mem-
bers are chitinase-like proteins (CLPs), which, as a result of
mutations in their highly conserved enzyme sites, do not contain
chitinase activity. Breast regression protein (BRP)–39 and its
human homolog, YKL-40 (also called chitinase-3–like 1 and
human cartilage glycoprotein–39) (21–23) are the prototypes of
these enzymatically deficient CLPs. They are produced by
a variety of cells, including neutrophils, monocytes, and macro-
phages (18, 21, 24). In addition, increased levels of YKL-40
protein and/or mRNA have been noted in patients with a wide
spectrum of pathologies, including bacterial infections, rheuma-
toid arthritis, osteoarthritis, giant cell arteritis, sarcoidosis,
scleroderma, diabetes, atherosclerosis, inflammatory bowel dis-
ease, and a variety of malignancies (18, 21, 24–29). In many of
these disorders, the levels of YKL-40 reflect the activity and
natural history of the disease (17, 27–29). This is nicely illustrated
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Although supplemental oxygen is a commonly prescribed
therapy, prolonged exposure to 100% oxygen is known to
cause hyperoxic acute lung injury (HALI). However, the
mechanisms that control HALI are inadequately under-
stood.
What This Study Adds to the Field
These studies demonstrate that the chitinase-like proteins,
breast regression protein–39 and YKL-40, are important
regulators of HALI in the murine and human lung.
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by studies from our laboratory and others, which have demon-
strated that elevated levels of YKL-40 are seen in patients with
asthma, which correlate with the levels of lung tissueYKL-40 and
disease severity (17). These studies also highlighted polymor-
phisms in the chitinase-3–like 1 gene that correlated with the
levels of circulating YKL-40, the presence of asthma, and
compromised lung function (30). Surprisingly, although oxi-
dant-induced injuries are believed to contribute to the patho-
genesis of many of these responses, the relationship(s) between
BRP-39/YKL-40 and oxidant injury has not been investigated.
We hypothesized that BRP-39/YKL-40 plays a critical role in
the pathogenesis of HALI. To test this hypothesis, we charac-
terized the hyperoxia-induced responses in wild-type (WT)
mice, mice with null mutations of BRP-39 (BRP-392/2), mice
that overexpress YKL-40 in a lung-specific fashion, and mice
that lack BRP-39 and produce transgenic YKL-40 only in the
respiratory epithelium. To assess the applicability of our murine
findings to humans, we also evaluated the levels of YKL-40 in
tracheal aspirates from premature babies receiving oxygen
supplementation for respiratory failure. These studies demon-
strate that hyperoxia is a potent inhibitor of BRP-39 expression
and production, and that BRP-39 and YKL-40 inhibit the toxic
effects of hyperoxia. In accord with these findings, it was also
demonstrated that the levels of tracheal YKL-40 are lower in
premature babies that develop bronchopulmonary dysplasia
(BPD) or die compared with those without these complications.
METHODS
Genetically Modified Mice
BRP-392/2 mice were generated and used as previously described (31).
The mice were generated on a mixed 129/C57BL/6 background and
subsequently bred for more than 10 generations onto a C57BL/6
background. Transgenic mice in which human YKL-40 was tightly
and inducibly overexpressed (CC10-rtTA-tTS-YKL-40) in a lung-
specific manner were generated with constructs and approaches that
have been previously described by our laboratory (31). Mice that
lacked BRP-39 and produced YKL-40 only in pulmonary epithelial
cells (CC10-rtTA-tTS-YKL-40/BRP-392/–) were generated by breed-
ing the CC10-rtTA-tTS-YKL-40 and BRP-392/– mice. Mice with
caspase-3–null mutations were kindly provided by Dr. Flavell (Dept.
of Immunobiology, Yale University School of Medicine). Animal
protocols were approved by the Yale University Institutional Animal
Care and Use Committee, the guidelines of which were followed for all
experiments.
Oxygen Exposure
Mice (4–6 wk old) were placed in cages in an airtight Plexiglas chamber
(55 3 40 3 50 cm), as described previously (6, 10, 32). Throughout the
experiment, they were given free access to food and water. Oxygen
levels were constantly monitored by an oxygen sensor, which was
connected to a relay switch incorporated into the oxygen supply circuit.
The inside of the chamber was kept at atmospheric pressure, and mice
were exposed to a 12-hour light–dark cycle.
Bronchoalveolar Lavage
Mice were killed, the trachea was isolated by blunt dissection, and
a small-caliber tube was inserted into the airway and secured. Two
volumes of 1 ml of phosphate-buffered saline (PBS) containing 0.1%
bovine serum albumin were instilled, gently aspirated, pooled, and
processed as previously described (5, 6, 33).
Immunohistochemistry
Immunohistochemistry (IHC) was undertaken with a polyclonal anti–
BRP-39, as previously described by our laboratory (34). Antibodies
against surfactant apoprotein C (Millipore, Billerica, MA) and CC10
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were used to identify
alveolar type II cells and airway epithelial cells, respectively. The
specificity of the staining was evaluated in experiments in which the
primary antiserum was not used and experiments that compared tissue
samples from WT and BRP-392/– animals.
Histological Analysis
The lungs were removed en bloc, inflated at 25-cm pressure with PBS
containing 0.5% low melting point agarose, fixed in Streck solution
(Streck, Omaha, NE), embedded in paraffin, sectioned, and stained.
Hematoxylin and eosin and Periodic acid-Schiff (PAS) stains were
performed in the Research Histology Laboratory of the Department of
Pathology at the Yale School of Medicine.
Immunoblot Analysis
Bronchoalveolar lavage (BAL; 50 mg) fluids and/or lung lysates were
subjected to immunoblot analysis with antibodies against inhibitor of
caspase-activated deoxyribonuclease (Chemicon International, Biller-
ica, MA), caspase-3 (Cell Signaling Technology, Danvers, MA) or
b-tubulin (Santa Cruz Biotechnology, Inc.), and the polyclonal rabbit
antiserum against BRP-39, as noted above. These samples were frac-
tionated by polyacrylamide gel electrophoresis, transferred to mem-
branes, and evaluated as described previously by our laboratory (35).
Quantification of BRP-39, CXCL-1, and CCL-2
The levels of BRP-39 in BAL or lung lysates were evaluated by ELISA
with an anti–BRP-39 rabbit polyclonal IgG for capture and biotinylated
anti–BRP-39, followed by horseradish peroxidase–labeled streptavidin
(GE Healthcare, Piscataway, NJ) for detection. This assay detects as
little as 50 pg/ml recombinant BRP-39. The levels of BAL fluid CXCL-1
and CCL-2 were measured by ELISA with commercial kits (R&D
Systems, Minneapolis, MN), as directed by the manufacturer.
mRNA Analysis
mRNA levels were assessed by real-time reverse transcriptase–polymerase
chain reaction, as previously described by our laboratory (36, 37). The
sequences for the primers that were used were obtained from Primer
Bank online (http://pga.mgh.harvard.edu/primerbank).
Terminal Deoxynucleotidyl Transferase–Mediated dUTP Nick
End Labeling Staining
DNA fragmentation and cell death were evaluated with terminal
deoxynucleotidyl transferase–mediated dUTP nick end labeling
(TUNEL) assays, as previously described by our laboratory (37).
8-Hydroxy-29Deoxyguanosine Staining
Immunohistochemical detection 8-hydroxy-29deoxyguanosine (8-
OHdG) was done using paraffin-embedded sections. The primary
antibody used was mouse anti28-OHdG (Santa Cruz Biotechnology,
Inc.). The DAKO ARK system (Carpinteria, CA) was used as per the
manufacturer’s instructions. Negative controls consisted of isotype-
matched control or rabbit serum.
Measurement of Tracheal Aspirate YKL-40
The tracheal aspirate samples were collected from neonates admitted to
the Yale–New Haven Children’s Hospital Newborn Special Care Unit.
All infants had respiratory distress syndrome (RDS), which required
them to be intubated, and administered at least one dose of natural
surfactant and ventilated for treatment, per standard nursery guidelines.
BPD was defined as the need for oxygen with characteristic radiographic
changes at 36-weeks postmenstrual age. Samples were stored at 2708C
until assayed with ELISA. All human work was approved by the Human
Investigational Committee at Yale University School of Medicine.
In Vitro Oxygen Exposure
Human bronchial epithelial cell line BEAS-2B cells (ATCC, Rockville,
MD) were incubated in complete bronchial epithelial basal medium
(Lonza, Walkersville, MD). They were placed in an airtight modular
incubator chamber (Billups-Rothenberg, Del Mar, CA), which had
been flushed continuously with 95% O2/5% CO2 until the oxygen level
inside the chamber reached approximately 95%. The incubator cham-
ber was then placed in a tissue culture incubator at 378C, the O2 inside
the chamber was replaced every 24 hours, and the cells were harvested
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at the desired time points (24–72 h). The responses in these cells were
compared with events in cells incubated in 5% CO2 and air. In select
experiments, the cells were incubated with N-acetyl-L-cysteine (Sigma,
St. Louis, MO), which was added at a dose of 10 mM 1 hour before
oxygen exposure, or its vehicle control.
Statistical Analysis
All data were initially checked for normal/parametric distribution
(Kolmogorov-Smirnov test). If parametric distribution was found,
analysis of variance was applied to screen for differences among at
least three groups. To compare two individual groups, Student’s t test
was applied. If nonparametric distribution was found, the Kruskal-
Wallis test was applied to screen for differences among at least three
groups, followed by the Mann-Whitney U test (Wilcoxon rank-sum
test) to compare two individual groups. The survival rate was analyzed
by the Kaplan-Meier method. Statistical significance was defined at a P
value less than 0.05. All statistical analyses were performed with SPSS
version 13.0 (SPSS Inc., Chicago, IL).
RESULTS
Hyperoxia Inhibition of BRP-39 In Vivo
To begin to address our hypothesis, we compared the expres-
sion of BRP-39 in lungs from WT mice exposed to room air
(RA) and 100% O2. BRP-39 mRNA was readily appreciated in
lungs (Figure 1A), and BRP-39 protein was abundant in BAL
fluids from mice breathing RA (Figures 1B and 1C). IHC
demonstrated that this BRP-39 was most readily appreciated
in pulmonary macrophages and alveolar type 2 cells from these
mice (Figure 1D and data not shown). In contrast, hyperoxia
caused a significant decrease in BRP-39 mRNA and lung,
macrophage, and alveolar type 2 cell BRP-39 protein accumu-
lation (Figures 1A–1D). This inhibition was seen after as little
as 24 hours, and was most prominent after 72 hours of exposure
to 100% O2 (Figure 1E). It was only partially BRP-39 specific,
because similar inhibition of chitotriosidase expression was
noted (data not shown). These studies demonstrate that hyper-
oxia inhibits macrophage and epithelial cell BRP-39 expression
and accumulation in the murine lung.
Hyperoxia Inhibition of BRP-39 In Vitro
To further define the mechanism by which hyperoxia inhibits
BRP-39/YKL-40, we quantitated the expression of YKL-40 in
BEAS-2B cells in RA or 95% oxygen, and evaluated the effects
of antioxidants on these regulatory events. In keeping with our
in vivo findings, hyperoxia inhibited YKL-40 expression in
a time-dependent manner (Figure 1F). Importantly, pretreat-
ment with the antioxidant, N-acetyl-L-cysteine, abrogated the
YKL-40–inhibiting effects of hyperoxia (Figure 1G). These
studies demonstrate that hyperoxia inhibits epithelial cell
YKL-40 expression via an oxidant-dependent mechanism.
BRP-39 Inhibition of HALI
We next compared the effects of 100%O2 inWT and BRP-392/2
mice. As previously described by our laboratory and others (6,
7, 10–14), exposure to 100% O2 caused ALI, with alveolar
capillary permeability alterations characterized by increased
Figure 1. Hyperoxia regulation of breast
regression protein (BRP)–39. Mice were ex-
posed to room air (RA) or 100% O2 for up
to 72 hours (A–E). The levels of BRP-39
mRNA were evaluated by real-time reverse
transcriptase–polymerase chain reaction
(RT-PCR) (A). BRP-39 protein accumulation
was assessed via Western analysis (B) and
ELISA (C and E ) with bronchoalveolar lavage
fluid and lung lysates, respectively. Immu-
nohistochemistry was used to localize the
BRP-39 (D; closed arrows, alveolar type II
cells; open arrow, macrophage). BEAS-2B
cells were exposed to 95% O2 in the pres-
ence or absence of N-acetyl-L-cysteine
(NAC). Real-time RT-PCR was used to eval-
uate the effects of this exposure on YKL-40
expression (F ) and the effects of NAC in this
setting (G). The values in A, C, and E
represent the mean (6SEM) of evaluations
in a minimum of five animals. The values in F
and G represent the mean (6SEM) of trip-
licate experiments. (B) Representative of two
separate experiments. (D) Representative of
four similar evaluations. Scale bar 5 50 mm.
*P , 0.05, **P , 0.01.
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levels of BAL protein. This alveolar capillary protein leak was
seen after as little as 24 hours, and progressed over the first 72
hours of 100% O2 exposure (Figures 2A and 2B). With con-
tinued exposure, these lesions progressed, causing WT mice to
begin to expire after 4 days of 100% O2 exposure (Figures 2C
and 2D). Interestingly, BRP-392/2 mice had an exaggerated
response to hyperoxia. This manifested as enhanced protein
leak (Figure 2B) and premature death after 100% O2 exposure
(Figures 2C and 2D). These responses were not strain specific,
because augmented HALI and accelerated death were seen in
BRP-392/2 mice on C57BL/6 and Balb/c backgrounds (Figures
2C and 2D and data not shown). Thus, BRP-39 is an important
inhibitor of HALI.
BRP-39 Inhibition of Hyperoxia-induced Inflammation
and Cytokine Production
We also compared the BAL and tissue inflammatory responses in
WT and BRP-392/2 mice breathing RA or 100% O2. In WT
mice, hyperoxia increased BAL total cell, macrophage, and
neutrophil recovery, and induced a neutrophil- and macro-
phage-rich tissue inflammatory response (Figures 3A–3C). In
accord with their chemotactic properties for neutrophils and
macrophages, these alterations were associated with significant
increases in the levels of keratinocyte chemoattractant (KC)/
CXCL1 and monocyte chemoattractant protein (MCP)-1/CCL-2,
respectively (Figures 3D and 3E). Importantly, BRP-39 played
an important role in these alterations, because BAL total cell,
macrophage and neutrophil recovery, tissue inflammation, and
KC/CXCL1 and MCP-1/CCL-2 production were enhanced in
BRP-392/2 mice breathing 100% O2 (Figures 3A–3E). These
studies demonstrate that BRP-39 also inhibits hyperoxia-induced
tissue inflammation and chemokine production.
BRP-39 Inhibition of Hyperoxia-induced Oxidant
Injury and Apoptosis
Because oxidant-induced DNA injury and cell death play impor-
tant roles in the pathogenesis of HALI (6, 7), the roles of BRP-39
in these responses were evaluated. In accord with this concept,
100%O2 caused oxidant injury that was readily apparent with 8-
OHdG tissue staining (Figure 4A), and DNA injury and cell
death that manifested as increased levels of tissue TUNEL
staining and caspase-3 activation (Figures 4B–4D and data not
shown). BRP-39 played a critical role in the pathogenesis of both
responses, because oxidant-induced tissue injury (8-OHdG stain-
ing), TUNEL staining, and caspase-3 activation were all signifi-
cantly increased in BRP-392/2 mice compared with WT mice
(Figures 4A–4D and data not shown). Combined TUNEL and
cell-specific IHC highlighted the alveolar and epithelial cell
apoptosis in the BRP-392/2mice in 100%O2 (Figure 4D). Thus,
BRP-39 is a critical mediator of hyperoxia-induced oxidant
injury, DNA injury, and cell death.
Transgenic YKL-40 Inhibition of HALI
To further define the effector functions of BRP-39 and its human
homolog, YKL-40, two approaches were used. In the first, we
bred theCC10-rtTA-tTS-YKL-40micewith theBRP-392/2mice
to generate CC10-rtTA-tTS-YKL-40/BRP-392/2 (BRP-392/2/
YKL-40 Tg) mice that did not produce BRP-39, and only
produced YKL-40 in the epithelium of the lung. This allowed us
to define the effects of YKL-40 in hyperoxia in the absence of
potentially confounding responses induced by endogenously
produced BRP-39. Transgenic YKL-40 enhanced the survival
of BRP-392/2mice exposed to 100% oxygen (Figure 5A). It also
gave us a clear window into the ability of YKL-40 to rescue the
augmented hyperoxia-induced responses in BRP-392/2 animals.
As noted previously here, 100% O2 caused exaggerated HALI
responses, with alveolar capillary permeability alterations, pro-
tein leak, tissue and BAL neutrophil- and macrophage-rich
inflammation, KC/CXCL-1 and MCP-1/CCL2 production,
a TUNEL-positive cell death response, and caspase-3 activation
in BRP-392/2 mice (Figures 5B–5H). These augmented re-
sponses in BRP-392/2 mice were restored to levels comparable
to those inWT animals by epithelial-targeted transgenic YKL-40
(Figures 5B–5H).
Figure 2. Role of breast regression protein (BRP)–39 in
hyperoxia-induced vascular permeability and premature
death. Wild-type (WT) (1/1) mice were exposed to 100%
O2 up to 72 hours, and bronchoalveolar lavage (BAL)
protein was quantitated (A). WT and BRP-392/2 mice
were exposed to 100% O2 for 72 hours, and BAL protein
was assessed (B). C57BL/6 (C ) and Balb/c (D) mice were
exposed to 100% O2, and survival was assessed. The
values in A and B are the mean (6SEM) of evaluations in
a minimum of five animals, and are representative of two
separate experiments. Data in C and D represent assess-
ments in a minimum of eight mice. NS, not significant.
*P , 0.05, **P , 0.01.
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Experiments were also undertaken with CC10-rtTA-tTS-
YKL-40 mice on a WT genetic background. These experiments
compared the hyperoxia-induced responses in mice with physio-
logic and supraphysiologic levels of BRP-39/YKL-40. The fea-
tures of the HALI that was seen in WT mice with physiologic
levels of BRP-39 have been described previously here. Impor-
tantly, survival was enhanced (Figure 5I) and the alveolar
capillary permeability alterations, protein leak, tissue and BAL
inflammation, KC/CXCL-1 and MCP-1/CCL2 production,
TUNEL-positive cell death, and caspase-3 activation were di-
minished in theYKL-40Tg animals in 100%O2 (Figures 5B–5H).
When viewed in combination, these studies demonstrate that
epithelial-targeted YKL-40 inhibits the toxic manifestations of
100% O2 in the murine lung, and abrogates the exaggerated
HALI in lungs from BRP-392/2mice.
Caspase-3 Drives Inflammation in BRP-392/2 Mice
Exposed to 100% O2
To understand the relationship between the inflammation and
permeability and caspase activation in our modeling system, we
bredBRP-392/2 and caspase-32/2mice and compared the effects
of 100% O2 in WT mice, single mutant mice, and mice with null
mutations of BRP-39 and caspase-3 (BRP-392/2/caspase-32/2).
As noted previously here, hyperoxia caused a neutrophil- and
macrophage-rich inflammatory response in WT mice, which was
exaggerated in BRP-392/2 mice. Interestingly, BAL and tissue
inflammation were markedly ameliorated in the BRP-392/2/
caspase-32/2 mice (Figures 6A–6C and data not shown). Simi-
larly, hyperoxia caused alveolar capillary protein leak in WT
mice, which was exaggerated in BRP-392/2 animals (Figure 6D).
Interestingly, the hyperoxia-induced permeability changes inWT
mice, and the exaggerated permeability alterations in BRP-392/2
mice, were markedly ameliorated in mice that lacked caspase-3
(Figure 6D). These studies demonstrate that caspase-3, a critical
effector of apoptosis, plays an essential role in the pathogenesis of
the exaggerated inflammation and permeability alterations in
hyperoxia-exposed WT and BRP-392/2- animals.
Differences in the Levels of Tracheal Aspirate YKL-40
in Premature Newborns on Supplemental Oxygen
To determine if our murine findings are relevant to humans, we
measured the levels of YKL-40 in tracheal aspirates from pre-
mature newborns on mechanical ventilation and supplemental
oxygen due to respiratory failure. Because oxidant injury is
known to contribute to the pathogenesis of BPD (38), we
compared the tracheal YKL-40 in infants that developed BPD
Figure 3. Role of breast regression protein
(BRP)–39 in hyperoxia-induced inflammation
and chemokine production. Wild-type (WT)
(1/1) and BRP-392/2 mice were exposed to
100% O2 for 72 hours, and bronchoalveolar
lavage (BAL) total cell recovery (A), differential
cell recovery (B), lung histology (C; hematoxylin
and eosin stain), and the levels of BAL KC/
CXCL1 (D) and MCP-1/CCL-2 (E ) were
assessed. The values in A, B, D, and E represent
the mean (6SEM) of evaluations in a minimum
of five animals, and are representative of two
separate experiments. C is representative of five
similar evaluations. NS, nonsignificant. Scale
bar, 100 mm. *P , 0.05.
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or died with those that did not develop these complications.
Although there were no statistically significant difference be-
tween the ‘‘no BPD’’ (n5 4) and BPD/death (n5 5; two deaths)
groups in the use of antenatal steroids, delivery route, percent
male sex, gestational age, and the degree of oxygen supplemen-
tation (maximum FIO2), their birth weights were significantly
different (Table 1). There were also no significant differences in
the two groups in terms ofApgar scores at 1 and 5minutes and the
time of collection of tracheal aspirate samples. Expectedly,
babies in the BPD/death group had higher indices of severity of
lung disease, as exemplified by more doses of surfactant and
longer duration of invasive mechanical ventilation and exposure
to supplemental oxygen (Table 1). YKL-40 was readily apparent
in aspirates from premature babies being ventilated for RDS.
Interestingly, the levels of tracheal aspirate YKl-40 were signif-
icantly lower in the babies that subsequently developed BPD or
death compared with the babies that did not develop these
outcomes (P 5 0.01) (Figure 7). These studies demonstrate that
elevated levels of tracheal aspirate YKL-40 are associated with
improved pulmonary outcomes in premature neonates that are
on supplemental oxygen due to respiratory failure.
DISCUSSION
ALI and its most severe form, acute RDS (ARDS), are devas-
tating clinical syndromes affecting greater than 200,000 patients
per year in the United States alone (39). Despite recent advances
in therapy, the mortality for ARDS remains in the 25–50% range
(40). On the other end of the spectrum, BPD, in which HALI is
a critical contributing factor, is the commonest chronic lung
disease in infants (41). There are currently no specific or effective
interventions that prevent or ameliorate establishedBPD, and no
established biomarkers that predict its occurrence in premature
infants (41). In addition, although significant effort has been
directed at the mechanisms that underlie this disorder(s), our
understanding of the pathogenicmechanisms that are responsible
for these adverse events is highly incomplete. To address this
issue, we initiated studies that were designed to determine if the
CLPs, BRP-39 and YKL-40, regulate the ALI induced by the
prototypic oxidant, 100% O2. These studies demonstrate that
hyperoxia inhibits BRP-39 expression and production in the
otherwise naive murine lung and in epithelial cells in cluture.
They also demonstrate that mice that lack BRP-39 have exag-
gerated responses to 100% O2, manifested by augmented alveo-
lar–capillary permeability and protein leak, tissue oxidation,
neutrophil- andmacrophage-rich inflammation, chemokine elab-
oration, epithelial apoptosis, and premature death. Lastly, they
demonstrate that transgenic YKL-40 ameliorates HALI, pro-
longs survival in 100% O2, and rescues the exaggerated injury
response in BRP-392/2 animals. These studies highlight novel
relationships between BRP-39/YKL-40 and oxidants in the lung,
including the demonstration that oxidant injury decreases the
expression and production of BRP-39, and that BRP-39 and
YKL-40 are important inhibitors of oxidant-induced lung injury,
permeability, and structural cell apoptosis.
BRP-39/YKL-40 is a product of the CH3L1 gene on chromo-
some 1 in mice and humans that is found in significant quantities
in the circulation and tissues of normal humans and other animal
species. BRP-39 and YKL-40 are also highly inducible, with
elevated levels being seen in the serum and or tissues from
patientswith a variety of diseases, and elevated levels being noted
in epithelial cells and/or macrophages after stimulation with IL-
13 (31) and during late stages of macrophage activation (42).
Transcriptional mechanisms have been shown to contribute to
some of these stimulatory events (42). Surprisingly, our in vitro
and in vivo studies are the first to highlight a circumstance in
which the production and/or expression of BR-39/YKL-40 is
decreased. They are also the first to define the relationship
between this inhibition and oxidant injury, and to associate this
decrease with a pathologic tissue response. When combined with
our demonstration that BRP-39 inhibits HALI, one can envision
a scenario in which the decrease in BRP-39 that is seen contrib-
utes to the initiation and/or perpetuation of this oxidant injury
response. In light of our demonstration that transgenic YKL-40
Figure 4. Role of breast regression pro-
tein (BRP)–39 in hyperoxia-induced oxi-
dant and DNA injury. Wild-type (WT)
(1/1) and BRP-392/2 mice were ex-
posed to room air (RA) or 100% O2 for
72 hours, and subjected to 8-hydroxy-
29deoxyguanosine (8-OHdG) (A; closed
arrows, airway and alveolar type II epi-
thelial cells; open arrows, macrophage)
and terminal deoxynucleotidyl transferase–
mediated dUTP nick end labeling (TUNEL)
evaluation (B; closed arrows, alveolar type II
cells; open arrows, macrophage). TUNEL-
positive cells were counted and scored (C).
TUNEL-positive apoptotic cells were fur-
ther localized via double-label immunohis-
tochemistry with cell-specific antibodies
(CC10, airway epithelial cells; pro-SPC,
alveolar type II cells) and TUNEL staining
(D; arrows, double-stained cells). (A and B)
Representative composites of five similar
evaluations. The values in C are the mean
(6SEM) of evaluations in a minimum of
five animals, and are representative two
separate experiments. D is representative
of two separate experiments. Scale bar,
50 mm. NS, nonsignificant. *P , 0.05.
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inhibits HALI and reverses the exaggerated injury phenotype in
BRP-392/2 mice in 100% O2, one can also hypothesize that the
production of BRP-39/YKL-40 could increase during the later
phase of HALI, where it could feed back to inhibit the tissue
injury response. If future studies confirm these findings, one can
also speculate that interventions that increase BRP-39/YKL-40
may be therapeutically useful in the treatment of these disorders.
The glycosyl hydrolase (GH) 18 family contains chitinases and
CLPs, such asBRP-39 andYKL-40,which lack enzymatic activity
(43). They are widely expressed, being seen in archea, pro-
karyotes, and eurkaryotes (44). Mammals do not contain or
synthesize chitin, yet the human genome has eight GH-18 family
members (44). Although it is presumed that the physiologic roles
of these chitinases and CLP have resulted in their conservation
over these vastly different species, the roles of these molecules in
biology are poorly defined (43). Recent studies, however, have
shed light on important roles that chitinases and CLPs play that
may account for this conservation. Specifically, we demonstrated
that BRP-39 and YKL-40 inhibit the apoptosis of and CD95
expression by inflammatory cells at sites of Th2- and IL-13–
induced inflammation (31). We also demonstrated that acidic
mammalian chitinase, a true chitinase, can also inhibit epithelial
cell apoptosis, and that this inhibition is independent of the
chitinolytic effects of the enzyme (45). The present studies add to
Figure 5. Effects of
transgenic YKL-40 on
hyperoxia-induced bron-
choalveolar lavage (BAL)
and tissue responses.
Wild-type (WT) (1/1)
mice, mice with null
mutations of breast re-
gression protein (BRP)–
39 (BRP-392/2) mice,
and BRP-392/2 mice
that express transgenic
YKL-40 only in respira-
tory epithelium (BRP-
392/2/YKL-401 mice)
were exposed to room
air (RA) or 100% O2. (A
and I) Survival was
assessed. After 72 hours
of hyperoxia, BAL total
cell recovery (B), dif-
ferential cell recovery
(C ), the levels of BAL
KC/CXCL1 (D) and
MCP-1/CCL-2 (E ), lung
tissue histology (F; hema-
toxylin and eosin stain),
and the percentage
of terminal deoxynu-
cleotidyl transferase–
mediated dUTP nick
end labeling (TUNEL)–
positive cells (G) were
also assessed. Capase-3
activation and ICAD
cleavage were evalu-
ated (H). The data in A
and I represent assess-
ments in a minimum of
eight mice. The values
in B–E and G are the
mean (6SEM) of evalu-
ations in a minimum of
five animals, and are rep-
resentative of two sepa-
rate experiments. (F and
H) Representative of four
similar evaluations. Scale
bars, 100 mm. *P, 0.05.
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our understanding of the relationship(s) between BRP-39/YKL-
40 andapoptosis by demonstrating that these chilectins inhibit the
oxidant-induced cell death of alveolar type II cells. Although the
mechanism of this protection is not clear, it is tempting to
speculate that the phosphatidylinositol 3 kinase–Akt pathway is
involved, because studies fromour laboratory have demonstrated
that BRP-39/YKL-40 is a potent activator of Akt (31), and Akt
can confer cytoprotection in HALI (46–49). In combination,
these studies allow for the speculation that BRP-39 and YKL-40
are critical regulators of cell death that inhibit oxidant injury and
confer structural cell cytoprotection at physiologic concentra-
tions, and prolong the survival of inflammatory cells, and
contribute to antigen sensitization, chronic inflammation, and
tissue remodeling when elevated.
IL-13 is a critical effector at sites ofTh2-drivenpathologies.As
a result, anti–IL-13–based therapies are being developed to treat
a variety of diseases and disorders. To fully understand the
consequences of these interventions, studies have been under-
taken to define the beneficial effects of IL-13 in the lung. These
studies demonstrated that IL-13 is an important inhibitor of
oxidant-induced lung injury (50). The mechanism of this re-
sponse, however, is poorly understood. Recent studies from our
laboratory demonstrated that IL-13 is a potent stimulator of
BRP-39 (31). This raises the intriguing possibility that the pro-
tective effects of IL-13 in hyperoxia are mediated, at least in part,
by BRP-39/YKL-40.
ALI and ARDS are complex, multigenic, and multifactoral
disorders, with profound clinical heterogeneity (40). Neverthe-
less, progress has been made in the identification of genetic
variants that contribute to these responses and enhance our
understanding of the pathways that are involved in the patho-
genesis of these disorders. Using predominantly a candidate gene
approach, investigators have highlighted the importance of poly-
morphisms in a wide variety of genes, including those that encode
cytokines, blood pressure regulators, immune regulators, gene
transcription, coagulation, and antioxidants (40). Our studies
demonstrate that BRP-39 is inhibited during HALI and, in turn,
feeds back to inhibit HALI. Recent studies from our laboratory
and others have demonstrated that polymorphisms in theCH3L1
gene correlate with the levels of circulatingYKL-40, the presence
of asthma, and asthma severity (17, 30, 51). The present studies
raise the possibility that polymorphisms in YKL-40 also play an
important role in the pathogenesis of ALI and/or ARDS. This is
an intriguing possibility, because polymorphisms in themannose-
binding lectin, which, like YKL-40, is a circulating carbohydrate-
binding protein, have recently been shown to correlate with
Figure 5. (Continued ).
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ARDS (52–54). In addition, if CH3L1 polymorphisms correlate
with asthma andHALI, this would add to the mounting evidence
supporting the ‘‘common variant/multiple disease hypothesis,’’
which suggests that certain disease genes may not be disease
specific, and may contribute to related clinical phenotypes (55).
In animal models of ALI, inflammation and lung injury are
frequently juxtaposed. This led to studies investigating the
mechanisms of hyperoxia-induced inflammation, and the re-
lationship between injury and inflammation in this disorder (11,
56, 57). Our studies have added to our understanding in this
area by highlighting an interesting relationship between the cell
death and inflammatory responses in this modeling system.
Specifically, they demonstrate that null mutations of caspase-3
diminish the inflammatory response induced by hyperoxia. This
suggests that cell death drives, at least in part, the inflamma-
tion in the lungs of mice breathing 100% O2. Under classic
conditions, apoptosis was proposed to be an inflammation-
independent form of cell death (58). However, it is now clear
that cells die via complex mechanisms, and that apoptotic cells
can undergo secondary necrosis if not rapidly cleared by
phagocytes (59). It is also clear that, during these responses,
injured cells elaborate a number of danger signals, which can
induce inflammation by activating Toll-like receptor 3 and C-
type lectin receptors (59). In accord with this scenario, the cell
Figure 6. Roles of caspase-3 in breast
regression protein (BRP)–39 regulation
of hyperoxia-induced responses. Wild-
type (WT) (1/1) mice, BRP-392/2 mice,
caspase-32/2 mice, and BRP-392/2/
caspase-32/2 mice were exposed to
room air (RA) or 100% O2 for 72 hours,
and bronchoalveolar lavage (BAL) total
cell recovery (A), BAL macrophage re-
covery (B), BAL neutrophil recovery (C),
and BAL protein (D) were assessed. The
values represent the mean (6SEM) of
evaluations in a minimum of five ani-
mals, and are representative of two sep-
arate experiments. Casp 3 5 caspase-3.
*P , 0.05.
TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF
THE STUDY GROUPS (NO BRONCHOPULMONARY DYSPLASIA
AND BRONCHOPULMONARY DYSPLASIA OR DIED)
No BPD BPD or Died
(n 5 4) (n 5 5) P Value
Prenatal steroids, % 3 (75) 5 (100) 0.44
C-section delivery, % 3 (75) 5 (100) 0.44
Male sex, % 1 (25) 3 (60) 0.52
Gestational age, wk 26.2 6 1.8 26.3 6 1.6 0.92
Birth weight, g 898 6 111 704 6 81 0.02
Apgar @ 1 min < 3, % 1 (25) 2 (40) 1.00
Apgar @ 5 min < 7, % 1 (25) 1 (20) 1.00
TA sample collected, d 2.3 6 1.3 2.4 6 1.7 0.89
Maximum FIO2 (on TA
sample collection day)
0.27 6 0.02 0.30 6 0.04 0.49
Survanta, doses 1.0 6 0.0 2.2 6 0.8 ,0.05
ETT PPV, d 7.3 6 8.8 43.8 6 11.4 0.001
Oxygen, d 28.8 6 10.1 68.0 6 16.9 0.005
Length of hospitalization, d 65.0 6 14.5 68.4 6 16.9 0.76
Definition of abbreviations: BPD 5 bronchopulmonary dysplasia; ETT PPV 5
endotracheal tube positive pressure ventilation; TA 5 tracheal aspirate.
Values are expressed as means (6SD).
Figure 7. YKL-40 protein in tracheal aspirates from premature babies
with respiratory failure requiring mechanical ventilation and O2 sup-
plementation. The levels of YKL-40 were evaluated by ELISA. The values
represent the mean (6SEM) of evaluations in patients that developed
bronchopulmonary dysplasia (BPD) or died (n 5 5) and those that did
not develop these complications (No BPD; n 5 4). *P , 0.05.
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death response in this oxidant injury model has been extensively
studied and shown to have features of both apoptosis and
necrosis (14, 60, 61).
RDS and respiratory failure are problematic consequences of
premature birth. Patients with these conditions are commonly
treated with mechanical ventilation, supplemental oxygen, and
surfactant preparations (62), and, in many cases, rapidly recover.
However, in a subset of patients, oxidant injury contributes to the
development of BPD with chronic respiratory failure, and death
can ensue (41). To determine if our murine findings are relevant
to human disease, we compared the levels of tracheal aspirate
YKL-40 in a cohort of premature babies with RDS that de-
veloped BPD or died, and premature infants with milder disease
that did not experience these adverse consequences. In this
cohort, the premature infants with the milder disease had higher
levels of this CLP. These observations are in accord with our
finding that YKL-40 inhibits HALI. If they are confirmed in
subsequent, larger studies, they also raise the possibility that the
elevated levels of YKL-40 are causally related to the milder
disease in these individuals.Oxidant injury also plays amajor role
in the pathogenesis of interstitial lung diseases, asthma, and
chronic obstructive pulmonary disease and canworsen the effects
of pulmonary infections (63–67). When viewed in combination,
these observations allow for the speculation that BRP-39/YKL-
40 may be able to be manipulated to control oxidant-induced
pulmonary responses, and that the levels of circulating and or
organ YKL-40 might be useful biomarkers that can predict the
severity and or course of these disorders. For example, in
premature newborns, YKL-40 might be able to be used as
a therapeutic in infants with RDS to prevent or ameliorate
BPD, and the levels of tracheal aspirate YKL-40 might predict
who will develop BPD and who will not. These studies also
suggest that genetic polymorphisms, environmental exposures,
or pharmacologic interventions that alter the levels and/or
effects of BRP-39/YKL-40 can have major effects on an in-
dividual’s ability to tolerate an oxidative load, and thus contrib-
ute to the severity and/or natural history of these disorders.
Additional investigations of the regulation and roles of chiti-
nases and CLP in oxidant-induced injury and subsequent repair,
and the feasibility and utility of CLP-based therapeutic manip-
ulations, are warranted.
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